Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2011

Global Markets Direct, December 2011, Pages: 41

Neonatal Respiratory Distress Syndrome – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2011', provides an overview of the Neonatal Respiratory Distress Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Neonatal Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neonatal Respiratory Distress Syndrome. 'Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neonatal Respiratory Distress Syndrome.
- A review of the Neonatal Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neonatal Respiratory Distress Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neonatal Respiratory Distress Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neonatal Respiratory Distress Syndrome pipeline depth and focus of Neonatal Respiratory Distress Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Neonatal Respiratory Distress Syndrome Therapeutic Products under Development, Key Players in Neonatal Respiratory Distress Syndrome Therapeutics, Neonatal Respiratory Distress Syndrome Pipeline Overview, Neonatal Respiratory Distress Syndrome Pipeline, Neonatal Respiratory Distress Syndrome Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neonatal Respiratory Distress Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Neonatal Respiratory Distress Syndrome
Neonatal Respiratory Distress Syndrome Therapeutics under Development by Companies
Neonatal Respiratory Distress Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Neonatal Respiratory Distress Syndrome Therapeutics – Products under Development by Companies
Neonatal Respiratory Distress Syndrome Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Neonatal Respiratory Distress Syndrome Therapeutics Development
Discovery Laboratories, Inc.
Faron Pharmaceuticals, Ltd.
Neonatal Respiratory Distress Syndrome – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Surfaxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Surfaxin LS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Betamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Betamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon beta for neonatal respiratory distress syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Surfactant + Vitamin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neonatal Respiratory Distress Syndrome Therapeutics – Drug Profile Updates
Neonatal Respiratory Distress Syndrome – Product Development Milestones
Neonatal Respiratory Distress Syndrome – Product Development Milestones
Featured News & Press Releases
Sep 06, 2011: Discovery Labs Submits SURFAXIN Complete Response To FDA
May 05, 2010: Discovery Lab's Surfaxin LS Improves Pulmonary Function And Reduces Lung Inflammation In Established Model Of RDS
May 05, 2009: Discovery Labs’ Surfaxin Significantly Improves Lung Surfactant Distribution In Preclinical RDS Model
May 05, 2009: Discovery Labs’ Surfaxin Significantly Improves Lung Surfactant Distribution In Preclinical RDS Model
May 31, 2007: Discovery Laboratories, Inc Announced Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published In Pediatrics
May 31, 2007: Discovery Laboratories, Inc Announced Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published In Pediatrics
May 18, 2005: Discovery Laboratories, Inc Announced New Data of Surfaxin Survival Benefit Continues Through One Year Of Life
May 18, 2005: Discovery Laboratories, Inc Announced New Data of Surfaxin Survival Benefit Continues Through One Year Of Life
Feb 14, 2005: Discovery Labs Receives Approvable Letter From FDA For Surfaxin For Respiratory Distress Syndrome In Premature Infants
Feb 14, 2005: Discovery Labs Receives Approvable Letter From FDA For Surfaxin For Respiratory Distress Syndrome In Premature Infants
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Neonatal Respiratory Distress Syndrome, H2 2011
Products under Development for Neonatal Respiratory Distress Syndrome – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Discovery Laboratories, Inc., H2 2011
Faron Pharmaceuticals, Ltd., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Neonatal Respiratory Distress Syndrome Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Neonatal Respiratory Distress Syndrome, H2 2011
Products under Development for Neonatal Respiratory Distress Syndrome – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012
• Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Neonatal Respiratory Distress Syndrome - Pipeline Review, H1 2012
• Neonatal Respiratory Distress Syndrome - Pipeline Review, Q2 2011
• Respiratory Distress Syndrome - Pipeline Review, H1 2012
• Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011
• Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013